Never miss a story

Get subscribed to our newsletter


×
According to the WHO, there is "at this time no connection" between the AstraZeneca vaccine and blood clots. Pixabay

There is a causal link between the coronavirus vaccine developed by AstraZeneca and very rare cases of blood clots, although it remains unclear what the connection is and the possible causes are likewise still unknown, a senior European Medicines Agency (EMA) expert told an Italian on Tuesday.

“It is clear that an association exists” between the vaccine and the dozens of reported blood clots, said Marco Cavaleri, head of the EMA’s health threats and vaccines strategy.


“Such cases are extremely rare, and the benefits (of the vaccine) still largely outweigh the risks,” he stressed.

Follow NewsGram on LinkedIn to know what’s happening around the world.

“Yet, it is becoming increasingly hard to say there is no cause-effect relationship between the vaccination with AstraZeneca and very rare cases of unusual blood clots associated with a low number of platelets,” he said.


The vaccine campaign in Italy is still going on, but it has been marred by delays and a late start. Pixabay

In its latest assessment of embolic and thrombotic events reported after coronavirus vaccination published on March 24, the EMA looked at 258 such cases (45 of them fatal) that occurred in Europe out of almost 20 million first doses of the vaccine administered, the Xinhua news agency reported.

On March 31, the agency explained that such an assessment did not unveil “any specific risk factors, such as age, gender or a previous medical history of clotting disorders for these very rare events.”

“A causal link with the vaccine is not proven but is possible, and further analysis is continuing,” it added.

Cavaleri told the Italian newspaper on Tuesday that the assessment process was “far from over.”

The EMA is expected to provide a new evaluation on the use of the AstraZeneca vaccine soon, perhaps by late Wednesday, the European Union’s (EU) Health Commissioner Stella Kyriakides said on Twitter on Tuesday.


European Union’s (EU) Health Commissioner, Stella Kyriakides. Wikimedia Commons

Meanwhile, the Italian Medicines Agency (AIFA) and the Health Ministry were also due to discuss the issue late on Tuesday, although the AIFA would reportedly not issue any new rule on the AstraZeneca vaccine’s use pending the EMA’s decision.

Like other EU countries, Italy on March 15 issued a “temporary and precautionary” ban on the use of the AstraZeneca vaccine following reports of a small number of clot deaths in the country.

Three days later, it resumed use of the AstraZeneca vaccine following the EMA’s announcement that it was safe.

Also in March, the Italian branch of AstraZeneca said that “an analysis of safety data on over ten million doses administered has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any age group, gender or batch.”

However, an official from the World Health Organization (WHO) said on Tuesday that there was “no link for the moment” between the AstraZeneca vaccine and blood clots, stressing that the benefits of the vaccine were “largely still positive” compared to its risks.


The AstraZeneca vaccine is one of four coronavirus vaccines officially approved in Italy. Pixabay

“We continue to see a number of events that are rare events. … There’s no evidence that the benefit-risk assessment for the vaccine needs to be changed,” said Rogerio Pinto de Sa Gaspar, Director of Regulation and Pre-qualification of WHO, at a press conference.

The AstraZeneca vaccine was authorized for use in Italy on January 29 and is one of four vaccines currently approved against the coronavirus here, the others being those by Pfizer/BioNTech, Moderna, and Johnson & Johnson.

ALSO READ: Healthy Body Weight, Good Cholesterol Likely To Lower Risk Of Covid19

Italy’s vaccination campaign is ongoing but it has been marred by a slow start and delays.

To date, the country has administered 11.3 million doses out of the 14.1 million doses available, according to the government. Over 3.5 million people have received both vaccine doses.

At a global level, 269 candidate vaccines are still being developed — 85 of them in clinical trials — in several countries including Germany, China, Britain, Russia, and the US, according to data released by the World Health Organization on April 2. (IANS/KB)


Popular

Unsplash

Robots evolve to do more work around us

As robots evolve to do more work around us, the UK-based humanoid robot manufacturer Engineered Arts has infused more human-like facial expressions into one of its robots, which may leave you with an eerie feeling.

In a video posted on YouTube, the robot called 'Ameca' displays various human expressions, like appearing to "wake up" from sleep, as its face shows confusion and frustration when it opens its eyes.

Follow NewsGram on Twitter to stay updated about the World news.

Keep Reading Show less
Unsplash

The Microsoft office

Microsoft has disrupted the activities of a China-based hacking group, gaining control of the malicious websites the group used to attack organisations in the US and 28 other countries around the world.

The Microsoft Digital Crimes Unit (DCU) said in a statement that a federal court in Virginia granted its request to seize websites of the hacking group called 'Nickel', enabling the company to cut off Nickel's access to its victims and prevent the websites from being used to execute attacks.

Keep Reading Show less
Unsplash

MediaTek's plans to boost technology democratisation and enable access to disruptive connectivity

Chip manufacturer MediaTek on Monday announced that it is focused on making 2022 a year aimed at rapid growth, business success, substantial expansion in Research and Development capabilities.

MediaTek's plans to boost technology democratisation and enable access to disruptive connectivity with its range of mainstream to flagship 5G chips.

"We at MediaTek are focused on making 2022 a year aimed at rapid growth, business success, and substantial expansion in our R&D capabilities. For 2022, we are focused on further strengthening our presence in India, offering incredible experiences to customers, and supporting the country's technology initiatives with our expertise and collaboration with leading OEMs," Anku Jain, Managing Director, MediaTek India said in a statement.

Follow NewsGram on LinkedIn to know what's happening around the world.

In the flagship segment, MediaTek recently announced the Dimensity 9000 chip, which is a milestone of innovation and a rise to the incredible, built-to-power flagship 5G smartphones in the world, the company claims.

MediaTek Dimensity 9000 features a single Cortex-X2 performance core clocked at 3.05GHz, three Cortex-A710 cores at 2.85GHz and four Cortex-A510 efficiency cores at 1.8GHz.

It packs a 10-core Arm Mali-G710 that takes care of graphics processing, the report said.

Keep reading... Show less